

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
**WO 2004/052094 A1**

- (51) International Patent Classification<sup>7</sup>: **A01K 67/033**, C07K 14/435, C12Q 1/68
- (74) Agent: **GRUBB, Phillip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (21) International Application Number:  
PCT/EP2003/014078
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (22) International Filing Date:  
11 December 2003 (11.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/432,854 12 December 2002 (12.12.2002) US
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- (71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG [CH/CH]**; Lichtstrasse 35, CH-4056 Basel (CH).
- Published:  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH [AT/AT]**; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **LI, Hao [US/US]**; 2 Strawberry Lane, Warren, NJ 07959 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHOD TO TREAT CONDITIONS ASSOCIATED WITH INSULIN SIGNALING DYSREGULATION**

(57) Abstract: The invention discloses a method to identify proteins involved in the insulin signaling pathway. The invention also discloses suitable targets for the development of new therapeutics to treat, prevent or ameliorate pathological conditions associated with dysregulation of the insulin signaling pathway. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor as well as to a method to identify compounds with therapeutic usefulness to treat pathological conditions associated with dysregulation of the insulin signaling pathway.

WO 2004/052094 A1